Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen

Anti-Cancer Drugs

Volumn 10, Issue 9, 1999, Pages 791-796

  Sarosdy, Michael F ^a,b  

^a University of Texas Health Science Center at San Antonio   (United States)

^b South Texas Urology and Urologic Oncology   (United States)

Author keywords

Antiandrogens; Bicalutamide; Flutamide; Nilutamide; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; LEUPRORELIN; NILUTAMIDE;

ADVANCED CANCER; ASTHENIA; BACKACHE; CASTRATION; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EDEMA; GYNECOMASTIA; HOT FLUSH; HUMAN; MALE; NAUSEA; ORCHIECTOMY; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; VOMITING;

EID: 0033408339     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199910000-00001     Document Type: Review

References (35)

1. 1. Bracci U. Antiandrogens in the treatment of prostatic cancer. Eur Urol 1979; 5: 303-6.
2. 2. Katchen B, Buxbaum S. Disposition of a new, nonsteroid, antiandrogen, alpha,alpha,alpha-trifluoro-2-methyl-4′-nitro-m-propionotoluidide (Flutamide), in men following a single oral 200 mg dose. J Clin Endocrinol Metab 1975; 41: 373-9.
3. 3. Brogden RN, Clissold S. Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer. Drugs 1989; 38: 185-203.
4. 4. Greenbergj R. Overview of patient compliance with medication: dosing: a literature review. Clin Ther 1984; 6: 592-9.
5. 5. Cockshott I, Cooper K, Sweetmore D, Blacklock N, Denis L. The pharrnacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol 1990; 18 (suppl 3): 10-7.
6. 6. Kaisary A. Compliance with hormonal treatment for prostate cancer. Br J Hosp Med 1996; 55: 359-66.
7. 7. Harris M, Coleman S, Faulds D, Chrisp P. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1993; 3: 9-25.
8. 8. Crawford ED, Eisenberger M, McLeod D, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24.
9. 9. Iversen P, Christensen M, Friis E, et al. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 1990; 66 (5 suppl): 1058-66.
10. 10. Denis L, Carneiro De Moura J, Bono A, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993; 42: 119-29.
11. 11. Zalcberg JR, Raghaven D, Marshall V, Thompson P. Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate - an Australian multicentre trial. Br J Urol 1996; 77: 865-9.
12. 12. Eisenberger MA, Blumenstein B, Crawford E, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42.
13. 13. Schellhammer PF, Sharifi R, Block N, et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology 1997; 50: 330-6.
14. 14. Sarosdy M, Schellhammer P, Sharifi R, et al. Comparison of goserelin and leuprolide in combined androgen blockade therapy. Urology 1998; 52: 82-8.
15. 15. Navratil H. Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study. Prog Clin Biol Res 1987; 243A: 401-10.
16. 16. Soloway M, Crawford E, Smith J, et al. A randomized, controlled trial of leuprolide and Anandron LA versus leuprolide and placebo for advanced prostate cancer. Eur Urol 1990; 18 (suppl): 99 (abstr 190).
17. 17. Brisset J, Boccon-Gibod L, Botto H, et al. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo. Prog Clin Biol Res 1987; 243A: 411-22.
18. 18. Beland G, Elhiali M, Fradet Y, et al. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma. Cancer 1990; 66 (5 suppl): 1074-9.
19. 19. Namer M, Toubol J, Caty A, et al. A randomized, double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer. J Steroid Biochem Mol Biol 1990; 37: 909-15.
20. 20. Janknegt R, Abbou C, Bartoletti R, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993; 149: 77-82.
21. 21. Bertagna C, de Géry A, Hucher M, et al. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients). Br J Urol 1994; 73: 396-402.
22. 22. Wysowski DK, JP F, Tourtelot J, Horton MD. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 1993; 118: 860-4.
23. 23. Wysowski D, Fourcroy J. Flutamide hepatotoxicity. J Urol 1996; 155: 209-12.
24. 24. Tyrrell C. Tolerability and quality of life aspects with the anti-androgen Casodex (ICI 176,334) as monotherapy for prostate cancer. International Casodex Investigators. Eur Urol 1994; 26 (suppl 1): 15-9.
25. 25. Kolvenbag G, Blackledge G. Worldwide activity and safety of bicalutamide: a summary review. Urology 1996; 47: 70-9.
26. 26. Schellhammer P. Bicalutamide (Casodex). Exp Opin Invest Drugs 1996; 5: 1707-22.
27. 27. Goa KL, Spencer C. Bicalutamide in advanced prostate cancer. A review. Drugs Aging 1998; 1212: 401-22.
28. 28. Schellhammer P, Sharifi R, Block N, et al. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. Urology 1995; 45: 745-52.
29. 29. Dawson LA, Chow E, Morton G. Fulminant hepatic failure associated with bicalutamide. Urology 1997; 49: 283-4.
30. 30. Schellhammer P. Fulminant hepatic failure associated with bicalutamide. Urology 1997; 50: 827.
31. 31. Chodak G. Bicalutamide-associated fulminant hepatic failure. Urology 1997; 50: 1027.
32. 32. McLeod D. Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997; 2: 18-27.
33. 33. Dole E, Holdsworth M. Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann Pharmacother 1997; 31: 65-75.
34. 34. Pfitzenmeyer P, Foucher P, Piard F, et al. Nilutamide pneumonitis: a report on eight patients. Thorax 1992; 622-7.
35. 35. Chatelain C, Rousseau V, Cosaert J. French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report. Eur Urol 1994; 26 (suppl 1): 10-4.